FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eric Freed

Research Profile

Living Beings

HIV-1
Virion

Chemicals & Drugs

Physiology

Anatomy

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Kirill A Afonin; Robert Blumenthal; Eric O Freed; Eliahu Heldman; Luc Jaeger; Stephen J Lockett; Anna E Maciag; Angelica N Martins; Mathias Viard; Bruce A Shapiro
Activation of different split functionalities on re-association of RNA-DNA hybrids.
Mary Ann Checkley; Simon Cocklin; Justin Donlan; Sampson K Kyere; Benjamin Luttge; Peter Y Mercredi; Tsutomu Murakami; Michael F Summers; Eric O Freed
Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.
Lillian Kuo; Eric O Freed
ARRDC1 as a mediator of microvesicle budding.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eric Freed (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kirill A Afonin; Robert Blumenthal; Eric O Freed; Eliahu Heldman; Luc Jaeger; Stephen J Lockett; Anna E Maciag; Angelica N Martins; Mathias Viard; Bruce A Shapiro
Activation of different split functionalities on re-association of RNA-DNA hybrids.
Nature nanotechnology 2013;8(4):296-304.
2013: Mary Ann Checkley; Simon Cocklin; Justin Donlan; Sampson K Kyere; Benjamin Luttge; Peter Y Mercredi; Tsutomu Murakami; Michael F Summers; Eric O Freed
Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.
Journal of virology 2013;87(6):3561-70.
2012: Lillian Kuo; Eric O Freed
ARRDC1 as a mediator of microvesicle budding.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(11):4025-6.
2012: Kayoko Waki; Scott L Butler; Stewart R Durell; Kunio Nagashima; Ferri Soheilian; Eric O Freed
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
PLoS pathogens 2012;8(11):e1002997.
2011: Jiyang Jiang; Sherimay Ablan; Suchitra Derebail; Eric O Freed; Robert J Gorelick; Kamil Hercík; Indira Hewlett; Kunio Nagashima; Ferri Soheilian; Shixing Tang; James A Thomas; Judith G Levin
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.
Virology 2011;421(2):253-65.
2011: Muthukumar Balasubramaniam; Eric O Freed
New insights into HIV assembly and trafficking.
Physiology (Bethesda, Md.) 2011;26(4):236-51.
2011: Wuxun Lu; Karl Salzwedel; Dan Wang; Carl T Wild; Suvobrata Chakravarty; Eric O Freed; Feng Li
A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.
Antimicrobial agents and chemotherapy 2011;55(7):3324-9.
2010: Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
Virology 2010;400(1):137-44.
2010: Benjamin G Luttge; Eric O Freed
FIV Gag: virus assembly and host-cell interactions.
Veterinary immunology and immunopathology 2010;134(1-2):3-13.
2010: Abdul A Waheed; Sherimay Ablan; Raymond C Sowder; James D Roser; Carl P Schaffner; Elena Chertova; Eric O Freed
Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.
Journal of virology 2010;84(6):3121-6.
2010: Catherine S Adamson; Michael Sakalian; Karl Salzwedel; Eric O Freed
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
Retrovirology 2010;7():36.
2010: Fa Liu; Andrew G Stephen; Abdul A Waheed; Eric O Freed; Robert J Fisher; Terrence R Burke
Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.
Bioorganic & medicinal chemistry letters 2010;20(1):318-21.
2010: Catherine S Adamson; Eric O Freed
Novel approaches to inhibiting HIV-1 replication.
Antiviral research 2010;85(1):119-41.
2009: Adam E Bennett; Kedar Narayan; Dan Shi; Lisa M Hartnell; Karine Gousset; Haifeng He; Bradley C Lowekamp; Terry S Yoo; DONALD BLISS; Eric O Freed; Sriram Subramaniam
Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages.
PLoS pathogens 2009;5(9):e1000591.
2009: Ken Fujii; Utpal M Munshi; Sherimay Ablan; Dimiter Demirov; Ferri Soheilian; Kunio Nagashima; Andrew G Stephen; Robert J Fisher; Eric O Freed
Functional role of Alix in HIV-1 replication.
Virology 2009;391(2):284-92.
2009: Catherine S Adamson; Karl Salzwedel; Eric O Freed
Virus maturation as a new HIV-1 therapeutic target.
Expert opinion on therapeutic targets 2009;13(8):895-908.
2009: Abdul A Waheed; Eric O Freed
Lipids and membrane microdomains in HIV-1 replication.
Virus research 2009;143(2):162-76.
2009: Eric O Freed
Welcome to viruses: a new open-access, multidisciplinary forum for virology.
Viruses 2009;1(1):1-2.
2009: Anjali Joshi; Sherimay Ablan; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment.
Journal of virology 2009;83(11):5375-87.
2009: Catherine S Adamson; Kayoko Waki; Sherimay Ablan; Karl Salzwedel; Eric O Freed
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
Journal of virology 2009;83(10):4884-94.
2009: Catherine S Adamson; Eric O Freed
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.
Molecular interventions 2009;9(2):70-4.
2009: Anjali Joshi; Kunio Nagashima; Eric O Freed
Defects in cellular sorting and retroviral assembly induced by GGA overexpression.
BMC cell biology 2009;10():72.
2009: Abdul A Waheed; Akira Ono; Eric O Freed
Methods for the study of HIV-1 assembly.
Methods in molecular biology (Clifton, N.J.) 2009;485():163-84.
2008: Anjali Joshi; Utpal Munshi; Sherimay Ablan; Kunio Nagashima; Eric O Freed
Functional replacement of a retroviral late domain by ubiquitin fusion.
Traffic (Copenhagen, Denmark) 2008;9(11):1972-83.
2008: Abdul A Waheed; Sherimay Ablan; Ferri Soheilian; Kunio Nagashima; Akira Ono; Carl P Schaffner; Eric O Freed
Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.
Journal of virology 2008;82(19):9776-81.
2008: Catherine S Adamson; Eric O Freed
Recent progress in antiretrovirals--lessons from resistance.
Drug discovery today 2008;13(9-10):424-32.
2008: Anjali Joshi; Himanshu Garg; Kunio Nagashima; Juan Bonifacino; Eric O Freed
GGA and Arf proteins modulate retrovirus assembly and release.
Molecular cell 2008;30(2):227-38.
2008: Karine Gousset; Sherimay Ablan; Lori V Coren; Akira Ono; Ferri Soheilian; Kunio Nagashima; David E Ott; Eric O Freed
Real-time visualization of HIV-1 GAG trafficking in infected macrophages.
PLoS pathogens 2008;4(3):e1000015.
2008: Benjamin Luttge; Miranda Shehu-Xhilaga; Dimiter Demirov; Catherine S Adamson; Ferri Soheilian; Kunio Nagashima; Andrew G Stephen; Robert J Fisher; Eric O Freed
Molecular characterization of feline immunodeficiency virus budding.
Journal of virology 2008;82(5):2106-19.
2007: Ken Fujii; James H Hurley; Eric O Freed
Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1.
Nature reviews. Microbiology 2007;5(12):912-6.
2007: Abdul A Waheed; Eric O Freed
Influenza virus not cRAFTy enough to dodge viperin.
Cell host & microbe 2007;2(2):71-2.
2007: Abdul A Waheed; Sherimay Ablan; James D Roser; Raymond C Sowder; Carl P Schaffner; Elena Chertova; Eric O Freed
HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(20):8467-71.
2007: Akira Ono; Abdul A Waheed; Eric O Freed
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.
Virology 2007;360(1):27-35.
2007: Shixing Tang; Sherimay Ablan; Megan Dueck; Wilfredo Ayala-López; Brenda Soto; Margaret Caplan; Kunio Nagashima; Indira K Hewlett; Eric O Freed; Judith G Levin
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein.
Virology 2007;359(1):105-15.
2007: Utpal M Munshi; Jaewon Kim; Kunio Nagashima; James H Hurley; Eric O Freed
An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains.
The Journal of biological chemistry 2007;282(6):3847-55.
2007: Catherine S Adamson; Eric O Freed
Human immunodeficiency virus type 1 assembly, release, and maturation.
Advances in pharmacology (San Diego, Calif.) 2007;55():347-87.
2006: Feng Li; Dorian Zoumplis; Claudia Matallana; Nicole Kilgore; Mary Reddick; Abdul S Yunus; Catherine S Adamson; Karl Salzwedel; David E Martin; Graham P Allaway; Eric O Freed; Carl T Wild
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Virology 2006;356(1-2):217-24.
2006: Catherine S Adamson; Sherimay Ablan; Ioana Boeras; Ritu Goila-Gaur; Ferri Soheilian; Kunio Nagashima; Feng Li; Karl Salzwedel; Michael Sakalian; Carl T Wild; Eric O Freed
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Journal of virology 2006;80(22):10957-71.
2006: Fa Liu; Andrew G Stephen; Catherine S Adamson; Karine Gousset; M Javad Aman; Eric O Freed; Robert J Fisher; Terrence R Burke
Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.
Organic letters 2006;8(22):5165-8.
2006: Abdul A Waheed; Sherimay Ablan; Marie K Mankowski; James E Cummins; Roger G Ptak; Carl P Schaffner; Eric O Freed
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.
The Journal of biological chemistry 2006;281(39):28699-711.
2006: Anjali Joshi; Kunio Nagashima; Eric O Freed
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation.
Journal of virology 2006;80(16):7939-51.
2006: Eric O Freed
HIV-1 Gag: flipped out for PI(4,5)P(2).
Proceedings of the National Academy of Sciences of the United States of America 2006;103(30):11101-2.
2006: William Fu; Que Dang; Kunio Nagashima; Eric O Freed; Vinay K Pathak; Wei-Shau Hu
Effects of Gag mutation and processing on retroviral dimeric RNA maturation.
Journal of virology 2006;80(3):1242-9.
2006: Eric O Freed; Andrew J Mouland
The cell biology of HIV-1 and other retroviruses.
Retrovirology 2006;3():77.
2005: Akira Ono; Abdul A Waheed; Anjali Joshi; Eric O Freed
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay.
Journal of virology 2005;79(22):14131-40.
2005: Peter A Sklar; Henry Masur; Jessica R Grubb; Jocelyn Voell; James Witek; Akira Ono; Eric O Freed; Frank Maldarelli
Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.
AIDS (London, England) 2005;19(10):1109-11.
2005: Akira Ono; Eric O Freed
Role of lipid rafts in virus replication.
Advances in virus research 2005;64():311-58.
2004: Dimiter Demirov; Eric O Freed
Retrovirus budding.
Virus research 2004;106(2):87-102.
2004: Eric O Freed
Mechanisms of enveloped virus release.
Virus research 2004;106(2):85-6.
2004: Akira Ono; Sherimay Ablan; Stephen J Lockett; Kunio Nagashima; Eric O Freed
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(41):14889-94.
2004: Evguenia S Svarovskaia; Hongzhan Xu; Jean L Mbisa; Rebekah Barr; Robert J Gorelick; Akira Ono; Eric O Freed; Wei-Shau Hu; Vinay K Pathak
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
The Journal of biological chemistry 2004;279(34):35822-8.
2004: Eric O Freed
HIV-1 and the host cell: an intimate association.
Trends in microbiology 2004;12(4):170-7.
2004: Akira Ono; Eric O Freed
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body.
Journal of virology 2004;78(3):1552-63.
2004: Eric O Freed; Susan R Ross
Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference.
Retrovirology 2004;1():25.
2004: Tsutomu Murakami; Sherimay Ablan; Eric O Freed; Yuetsu Tanaka
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
Journal of virology 2004;78(2):1026-31.
2004: Miranda Shehu-Xhilaga; Sherimay Ablan; Dimiter Demirov; Chaoping Chen; Ronald Montelaro; Eric O Freed
Late domain-dependent inhibition of equine infectious anemia virus budding.
Journal of virology 2004;78(2):724-32.
2003: Shixing Tang; Tsutomu Murakami; Naiqian Cheng; Alasdair C Steven; Eric O Freed; Judith G Levin
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.
Journal of virology 2003;77(23):12592-602.
2003: Feng Li; Ritu Goila-Gaur; Karl Salzwedel; Nicole Kilgore; Mary Reddick; C Matallana; A Castillo; D Zoumplis; David E Martin; Jan M Orenstein; Graham P Allaway; Eric O Freed; Carl T Wild
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(23):13555-60.
2003: Ritu Goila-Gaur; Dimiter Demirov; Jan M Orenstein; Akira Ono; Eric O Freed
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression.
Journal of virology 2003;77(11):6507-19.
2003: Eric O Freed
The HIV-TSG101 interface: recent advances in a budding field.
Trends in microbiology 2003;11(2):56-9.
2002: Eric O Freed
Viral late domains.
Journal of virology 2002;76(10):4679-87.
2002: Eric O Freed
Virology. Rafting with Ebola.
Science (New York, N.Y.) 2002;296(5566):279.
2002: Dimiter Demirov; Akira Ono; Jan M Orenstein; Eric O Freed
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(2):955-60.
2002: Dimiter Demirov; Jan M Orenstein; Eric O Freed
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.
Journal of virology 2002;76(1):105-17.
2001: Akira Ono; Eric O Freed
Plasma membrane rafts play a critical role in HIV-1 assembly and release.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):13925-30.
2001: Shixing Tang; T Murakami; B E Agresta; S Campbell; Eric O Freed; Judith G Levin
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.
Journal of virology 2001;75(19):9357-66.
2000: EK Halvas; Evguenia S Svarovskaia; Eric O Freed; Vinay K Pathak
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
Journal of virology 2000;74(14):6669-74.
2000: Akira Ono; Dimiter Demirov; Eric O Freed
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding.
Journal of virology 2000;74(11):5142-50.
2000: T Murakami; Eric O Freed
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.
Journal of virology 2000;74(8):3548-54.
2000: Akira Ono; Jan M Orenstein; Eric O Freed
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly.
Journal of virology 2000;74(6):2855-66.
2000: T Murakami; Eric O Freed
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(1):343-8.
1999: RE Kiernan; Akira Ono; Eric O Freed
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.
Journal of virology 1999;73(6):4728-37.
1999: Akira Ono; Eric O Freed
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.
Journal of virology 1999;73(5):4136-44.
1998: RE Kiernan; Eric O Freed
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations.
Journal of virology 1998;72(12):9621-7.
1998: RE Kiernan; Akira Ono; G Englund; Eric O Freed
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.
Journal of virology 1998;72(5):4116-26.
1997: Akira Ono; M Huang; Eric O Freed
Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions.
Journal of virology 1997;71(6):4409-18.
1997: Eric O Freed; G Englund; Frank Maldarelli; Malcolm Martin
Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection.
Cell 1997;88(2):171-3; discussion 173-4.
1996: R L Willey; Riri Shibata; Eric O Freed; Michael W Cho; Malcolm Martin
Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures.
Journal of virology 1996;70(9):6431-6.
1996: Eric O Freed; Malcolm Martin
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
Journal of virology 1996;70(1):341-51.
1995: M Huang; J M Orenstein; Malcolm Martin; Eric O Freed
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.
Journal of virology 1995;69(11):6810-8.
1995: Eric O Freed; G Englund; Malcolm Martin
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection.
Journal of virology 1995;69(6):3949-54.
1995: G Englund; T S Theodore; Eric O Freed; Alan Engelman; Malcolm Martin
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1.
Journal of virology 1995;69(5):3216-9.
1995: Eric O Freed; Malcolm Martin
Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.
Journal of virology 1995;69(3):1984-9.
1994: Eric O Freed; J M Orenstein; Alicia Buckler-White; Malcolm Martin
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.
Journal of virology 1994;68(8):5311-20.